Cargando…

Augmenting NF-κB in poor-risk CLL: A general paradigm for other cancers?

Detalles Bibliográficos
Autores principales:	Tuveson, David, Rai, Kanti R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2015
Materias:	News
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451126/ https://www.ncbi.nlm.nih.gov/pubmed/26034117 http://dx.doi.org/10.1084/jem.2126insight4

Ejemplares similares

Slow but steady for NF-κB
por: Leslie, Mitch
Publicado: (2012)

ECM controls flow-induced NF-κB
por: Tuma, Rabiya S.
Publicado: (2005)

NEMO surfaces in NF-κB–activating clusters
por: Leslie, Mitch
Publicado: (2014)

Rituximab mechanisms of action in B-CLL: a new piece of the puzzle
por: Watier, Hervé
Publicado: (2018)

Colon contradictions: NF-κB signaling in intestinal tumorigenesis
por: Fordham, Robert P., et al.
Publicado: (2015)

Reactivating nuclear PTEN to treat CLL
por: Bernardi, Rosa, et al.
Publicado: (2017)

Desmoplastic melanoma: C>Ts and NF‐κB
por: Rabbie, Roy, et al.
Publicado: (2016)

NF-kB and the CLL microenvironment
por: O’Donnell, Alice, et al.
Publicado: (2023)

Deciphering cancer fibroblasts
por: Biffi, Giulia, et al.
Publicado: (2018)

Targeted therapy in CLL: changing the treatment paradigm
por: Schneider, Christof, et al.
Publicado: (2019)

Genetic profiling of CLL: a ‘TP53 addict' perspective
por: Lodé, L, et al.
Publicado: (2016)

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
por: Haselager, Marco, et al.
Publicado: (2021)

Harnessing downstream NF-κB signalling to achieve apoptosis-inducing anti-cancer-specific activity
por: Vaccarezza, M, et al.
Publicado: (2016)

GPI-80 Augments NF-κB Activation in Tumor Cells
por: Takeda, Yuji, et al.
Publicado: (2021)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
por: Haselager, Marco V., et al.
Publicado: (2023)

A new paradigm for drug development
por: Burki, Talha
Publicado: (2020)

Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016)

The evolving treatment paradigm of lung cancer in China
por: Xie, Wei, et al.
Publicado: (2022)

A bacterial effector targets the TRAF6-NFκB pathway to modulate the acute inflammatory response to bacterial invasion of epithelial cells
por: Sanada, Takahito, et al.
Publicado: (2012)

CALPA-IN NF1
por: Lazar, Ikrame, et al.
Publicado: (2018)

NF-κB and tPA Signaling in Kidney and Other Diseases
por: White, Samantha, et al.
Publicado: (2020)

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2023)

Defining Emerging Roles for NF-κB in Antivirus Responses: Revisiting the Interferon-β Enhanceosome Paradigm
por: Balachandran, Siddharth, et al.
Publicado: (2011)

The NF-κB Pathway: Modulation by Entamoeba histolytica and Other Protozoan Parasites
por: Chadha, Attinder, et al.
Publicado: (2021)

Salivary gland branching morphogenesis: a quantitative systems analysis of the Eda/Edar/NFκB paradigm
por: Melnick, Michael, et al.
Publicado: (2009)

A New Paradigm to Mitigate Osteosarcoma by Regulation of MicroRNAs and Suppression of the NF-κB Signaling Cascade
por: Mongre, Raj Kumar, et al.
Publicado: (2014)

NF-Y joins E2Fs, p53 and other stress transcription factors at the apoptosis table
por: Gatta, R, et al.
Publicado: (2011)

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
por: Walsby, Elisabeth, et al.
Publicado: (2012)

NF-κB and Disease
por: Poma, Paola
Publicado: (2020)

NF-κB Members Left Home: NF-κB-Independent Roles in Cancer
por: Colomer, Carlota, et al.
Publicado: (2017)

In praise of other model organisms
por: Warren, Graham
Publicado: (2015)

News From Other Journals
por: Waldenstrom, Johan, et al.
Publicado: (1999)

Co‐expression of NF‐κB‐p65 and phosphorylated NF‐κB‐p105 is associated with poor prognosis in surgically resectable non‐small cell lung cancer
por: Lin, Gen, et al.
Publicado: (2018)

NF-κB-inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action
por: Sheng, Liang, et al.
Publicado: (2012)

Loss of NF-κB p50 function synergistically augments microglial priming in the middle-aged brain
por: Taetzsch, Thomas, et al.
Publicado: (2019)

NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression
por: Sim, Nicholas, et al.
Publicado: (2023)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

NF-κB and the Immunoglobulin κ Gene Enhancer
por: Sen, Ranjan
Publicado: (2004)

Katanin cuts some, spares others
por: LeBrasseur, Nicole
Publicado: (2007)

Analysis of variation in NF-κB genes and expression levels of NF-κB-regulated molecules
por: Liu-Mares, Wen, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_pjg2sp3mgpnk9il2c628eo9u28